Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia. [electronic resource]
Producer: 20070409Description: 475-85 p. digitalISSN:- 0007-1048
- Aged
- Alemtuzumab
- Antibodies, Monoclonal -- therapeutic use
- Antibodies, Monoclonal, Humanized
- Antibodies, Neoplasm -- therapeutic use
- Antigens, CD -- immunology
- Antigens, Neoplasm -- immunology
- Antineoplastic Agents -- therapeutic use
- CD4-Positive T-Lymphocytes -- drug effects
- CD52 Antigen
- CD8-Positive T-Lymphocytes -- drug effects
- Complementarity Determining Regions -- genetics
- DNA, Neoplasm -- genetics
- Female
- Follow-Up Studies
- Genes, T-Cell Receptor beta
- Glycoproteins -- immunology
- Humans
- Immunoglobulin Variable Region -- genetics
- Leukemia, Lymphocytic, Chronic, B-Cell -- drug therapy
- Male
- Middle Aged
- Pilot Projects
- Receptors, Antigen, T-Cell, alpha-beta -- genetics
- T-Lymphocyte Subsets -- drug effects
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.